Immutep Ltd ADR (IMMP) Stock Price, Quote & News

Company Profile

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung...

Industry: Biotechnology

Sector: Healthcare

Phone: 61 2 8315 7003

Fax: 61 2 8569 1880

Website: www.immutep.com

Address:

Australia Square, Level 32 264 George Street, Sydney, Australia

rispi Apr. 4 at 10:46 AM

Easter recap: $IMMP is dead and can easily go down another 50%; $TLSA is an hidden gem with insiders at almost half OS, funded for at least one year and plenty of readout; $TANH they are crazy, it’s a gamble; We’re also bullish on NatGas Henry Hub and European gas TTF. Best wishes

0 · Reply

rispi Apr. 4 at 10:39 AM

$IMMP Still waiting to know how much the shutdown of 004 will cost. Then we can calculate how much the r/s rate will be and how much money they need. No news, bad news

0 · Reply

USTradingTools Apr. 3 at 4:01 PM

$IMMP This is interesting me a lot

0 · Reply

revuelto Apr. 2 at 10:52 PM

$IMMP likely a reverse merger or an acquisition…bankruptcy’s off the table at this point…after this sharp drop, it’s one of the safer setups out there..

0 · Reply

NOCKNOCK Apr. 2 at 10:42 PM

$IMMP does this POS deserve to be in business anymore, I think would be a more appropriate question

0 · Reply

revuelto Apr. 1 at 7:45 PM

$IMMP does this market cap justify its assets and programs? zip and fly it will..

0 · Reply

theinvestaar Apr. 1 at 6:12 PM

$IMMP Let's go IMMP🔥🔥🔥🤙

1 · Reply

revuelto Apr. 1 at 2:39 PM

$IMMP appears to have stabilized..initiated a long position..

2 · Reply

rispi Apr. 1 at 1:18 PM

$IMMP ups! pre-market green??? common pumpers, out of your holes!!!

0 · Reply

LetsgoDudeszi Mar. 30 at 4:39 PM

$IMMP

1 · Reply

Immutep Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Sat, 04 Apr 2026 12:06:00 -0400 - 1 day ago

Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Fri, 03 Apr 2026 15:03:00 -0400 - 2 days ago

ROSEN, LEADING GLOBAL COUNSEL, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Thu, 02 Apr 2026 21:09:00 -0400 - 3 days ago

IMMP Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Thu, 02 Apr 2026 10:00:00 -0400 - 3 days ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP

Wed, 01 Apr 2026 17:45:00 -0400 - 4 days ago

ROSEN, A NATIONALLY RECOGNIZED INVESTOR RIGHTS LAW FIRM, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Wed, 01 Apr 2026 09:00:00 -0400 - 4 days ago

IMMP Investor Alert: Immutep Ltd. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Trial Futility: Levi & Korsinsky

Tue, 31 Mar 2026 18:20:00 -0400 - 5 days ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP

Mon, 30 Mar 2026 15:33:00 -0400 - 6 days ago

IMMP Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Mon, 30 Mar 2026 09:00:00 -0400 - 6 days ago

Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Mon, 30 Mar 2026 00:14:00 -0400 - 6 days ago

Lost Money on Immutep Limited (IMMP)? Possible Fraud - Contact Levi & Korsinsky Today

Sun, 29 Mar 2026 23:31:00 -0400 - 6 days ago

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Fri, 27 Mar 2026 16:48:00 -0400 - 9 days ago

IMMP Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Thu, 26 Mar 2026 10:00:00 -0400 - 10 days ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP

Wed, 25 Mar 2026 17:27:00 -0400 - 11 days ago

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Wed, 25 Mar 2026 09:00:00 -0400 - 11 days ago

IMMP Investor Alert: Immutep Ltd. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Trial Futility: Levi & Korsinsky

Tue, 24 Mar 2026 01:10:00 -0400 - 12 days ago

Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Mon, 23 Mar 2026 00:11:00 -0400 - 13 days ago

Fraud Investigation: Levi & Korsinsky Investigates Immutep Limited (IMMP) on Behalf of Shareholders

Sun, 22 Mar 2026 21:04:00 -0400 - 14 days ago

ROSEN, NATIONAL INVESTOR RIGHTS COUNSEL, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Mar 20, 2026, 8:00 PM EDT - 16 days ago

IMMP Investors Have Opportunity to Join Immutep Limited Fraud Investigation with the Schall Law Firm

IMMP

Wed, 18 Mar 2026 17:28:00 -0400 - 18 days ago

IMMP Investor Alert: Immutep Ltd. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Trial Progress: Levi & Korsinsky

Tue, 17 Mar 2026 15:15:00 -0400 - 19 days ago

Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation – IMMP

Tue, 17 Mar 2026 11:46:00 -0400 - 19 days ago

Ongoing Investigation into Immutep Limited (IMMP): Contact Levi & Korsinsky About Potential Fraud

Mar 16, 2026, 8:03 AM EDT - 20 days ago

Immutep Limited Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

IMMP

2026-03-13T17:23:35.000Z - 23 days ago

Immutep Stock Tanks After Futility Analysis Ends Key Lung Cancer Trial Early

2026-03-13T07:28:36.000Z - 23 days ago

Immutep Discontinues Phase III Trial Of Eftilagimod Alfa In First-Line NSCLC; Stock Drops

Feb 6, 2026, 8:00 AM EST - 2 months ago

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC

IMMP

Jan 29, 2026, 8:00 AM EST - 2 months ago

Immutep Quarterly Activities Report Q2 FY26

IMMP

Dec 22, 2025, 8:00 AM EST - 3 months ago

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study

IMMP

Dec 8, 2025, 2:34 AM EST - 4 months ago

India's Dr Reddy's signs licensing pact to sell Immutep's cancer drug

IMMP

Oct 20, 2025, 8:01 AM EDT - 5 months ago

Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025

IMMP

Sep 8, 2025, 8:00 AM EDT - 7 months ago

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

IMMP

Jul 30, 2025, 8:00 AM EDT - 8 months ago

Immutep Quarterly Activities Report Q4 FY25

IMMP

Jul 29, 2025, 8:00 AM EDT - 8 months ago

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

IMMP

May 27, 2025, 8:00 AM EDT - 11 months ago

Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

IMMP

May 15, 2025, 3:50 PM EDT - 11 months ago

Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo

IMMP

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Immutep to Participate in Upcoming Investor Conferences

IMMP

Jan 31, 2025, 8:00 AM EST - 1 year ago

Immutep Quarterly Activities Report Q2 FY25

IMMP

Dec 17, 2024, 8:00 AM EST - 1 year ago

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

IMMP

Dec 12, 2024, 8:15 AM EST - 1 year ago

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

IMMP

Nov 14, 2024, 11:16 AM EST - 1 year ago

Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial

IMMP

Nov 14, 2024, 8:15 AM EST - 1 year ago

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

IMMP

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Immutep Quarterly Activities Report Q1 FY25

IMMP

Oct 10, 2024, 8:00 AM EDT - 1 year ago

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

IMMP

Sep 16, 2024, 8:00 AM EDT - 1 year ago

Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

IMMP

Jul 31, 2024, 8:00 AM EDT - 1 year ago

Immutep Quarterly Activities Report Q4 FY24

IMMP

Jul 11, 2024, 6:40 PM EDT - 1 year ago

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

IMMP

Jul 3, 2024, 8:00 AM EDT - 1 year ago

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

IMMP

Jun 25, 2024, 8:00 AM EDT - 1 year ago

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

IMMP

Jun 5, 2024, 6:00 AM EDT - 1 year ago

Immutep successfully completes institutional placement and institutional component of entitlement offer

IMMP

Jun 2, 2024, 8:38 PM EDT - 2 years ago

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

May 15, 2024, 8:00 AM EDT - 2 years ago

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

May 2, 2024, 8:00 AM EDT - 2 years ago

Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Immutep Quarterly Activities Report Q3 FY24

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Apr 18, 2024, 8:00 AM EDT - 2 years ago

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Mar 5, 2024, 8:00 AM EST - 2 years ago

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Jan 30, 2024, 8:00 AM EST - 2 years ago

Immutep Quarterly Activities Report Q2 FY24

Jan 4, 2024, 8:00 AM EST - 2 years ago

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Dec 21, 2023, 8:00 AM EST - 2 years ago

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Dec 7, 2023, 8:00 AM EST - 2 years ago

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Nov 22, 2023, 8:00 AM EST - 2 years ago

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

Nov 9, 2023, 8:00 AM EST - 2 years ago

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Nov 6, 2023, 8:00 AM EST - 2 years ago

Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

Nov 3, 2023, 12:00 PM EDT - 2 years ago

Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Immutep to Participate in November Investor Events

Oct 31, 2023, 8:00 AM EDT - 2 years ago

Immutep Quarterly Activities Report Q1 FY24

Oct 25, 2023, 8:00 AM EDT - 2 years ago

Immutep receives ~A$1.13 million R&D Tax Incentive

Oct 24, 2023, 8:00 AM EDT - 2 years ago

Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023

Oct 23, 2023, 8:00 AM EDT - 2 years ago

Immutep's Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer

rispi Apr. 4 at 10:46 AM

0 · Reply

rispi Apr. 4 at 10:39 AM

$IMMP Still waiting to know how much the shutdown of 004 will cost. Then we can calculate how much the r/s rate will be and how much money they need. No news, bad news

0 · Reply

USTradingTools Apr. 3 at 4:01 PM

$IMMP This is interesting me a lot

0 · Reply

revuelto Apr. 2 at 10:52 PM

$IMMP likely a reverse merger or an acquisition…bankruptcy’s off the table at this point…after this sharp drop, it’s one of the safer setups out there..

0 · Reply

NOCKNOCK Apr. 2 at 10:42 PM

$IMMP does this POS deserve to be in business anymore, I think would be a more appropriate question

0 · Reply

revuelto Apr. 1 at 7:45 PM

$IMMP does this market cap justify its assets and programs? zip and fly it will..

0 · Reply

theinvestaar Apr. 1 at 6:12 PM

$IMMP Let's go IMMP🔥🔥🔥🤙

1 · Reply

revuelto Apr. 1 at 2:39 PM

$IMMP appears to have stabilized..initiated a long position..

2 · Reply

rispi Apr. 1 at 1:18 PM

$IMMP ups! pre-market green??? common pumpers, out of your holes!!!

0 · Reply

LetsgoDudeszi Mar. 30 at 4:39 PM

$IMMP

1 · Reply

ToRni27 Mar. 30 at 12:22 PM

$IMMP when 0?

1 · Reply

rispi Mar. 29 at 6:17 PM

$IMMP Careful, the way down is not finished. I wrote you plenty of times. Now I’m bullish on $TANH , setup seems ready.

0 · Reply

dgbio Mar. 27 at 3:59 PM

$IMMP This is not a batch problem. Immutep tried to get in the broadest 1st line possible in lung cancer. This was very ambitious but, if you look into P2 results, very risky. The margins over historic controls were not that large. Chemotherapy is a poor companion for efti. There are still large markets where anti-PD-1 drugs are used w/o chemo and efti should target these only. Immutep has an excellent IP portfolio, they should stop being ambitious, finally partner and go for the realistic goals.

1 · Reply

bylocehi Mar. 27 at 3:33 PM

$IMMP Reviewed issues with a guy who works for another biotech He said upgrades to large batches is a real problem with large molecular drugs like eftilagimod I am not selling until IMMP internal analysis complete If our Chinese partner, Wuxi, didn’t produce eftilagimod correctly would like to see company sold to someone who can make eftilagimod correctly.

0 · Reply

bylocehi Mar. 27 at 3:21 PM

$IMMP They been around since 1988 they know how to stay in business Marc is not an expert in getting drugs approved something we sorely need

0 · Reply

theinvestaar Mar. 27 at 2:41 AM

$IMMP Hello!!??? Management???

1 · Reply

rispi Mar. 26 at 10:25 AM

$IMMP phase ONE PR juicy

0 · Reply

LetsgoDudeszi Mar. 26 at 4:57 AM

$IMMP over 0.38 🍺🍺🍿 where da shorty”s at?

0 · Reply

theinvestaar Mar. 26 at 3:24 AM

$IMMP

0 · Reply

BullBobo Mar. 25 at 11:21 PM

$IMMP Managed to sell my entire holding 182,000 of this POS. Kept buying down and this goes down 5% everyday. Once you accumate enough share you would have difficulty selling it as there are NO buyer. Good luck if you still belive in this GARBAGE.

0 · Reply

theinvestaar Mar. 25 at 10:34 PM

$IMMP Let's go Marc!!!

1 · Reply

LetsgoDudeszi Mar. 25 at 6:05 PM

$IMMP pump is coming !

0 · Reply

Market Cap	53.28M
Revenue (ttm)	6.69M
Net Income (ttm)	-39.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-594.62%
Debt to Equity Ratio	0.01

Volume	284,400
Avg Vol	1,514,998
Day's Range	N/A - N/A
Shares Out	147.37M
Stochastic %K	38%
Beta	2.16
Analysts	Sell
Price Target	$1.00